20 June 2016 - The agenda for the 20-23 June 2016 CHMP meeting is now available.

The CHMP is scheduled to issue initial opinions for the following new medicines/combination products:

• Fluticasone propionate with salmeterol xinafoate
• Atazanavir sulphate
• Reslizumab
• Methotrexate
• Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor and the herpes simplex I virus thymidine kinase

For more details, go to: http://www.ema.europa.eu/docs/en_GB/document_library/Agenda/2016/06/WC500209036.pdf